Biohaven touts a pair of PhIII wins for migraine pill, but shares ricochet off of weak data
Biohaven has released a set of positive Phase III data for their fast-acting migraine drug, which closely parallel a rival at Allergan and trail well …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
